This site is intended for health professionals only
Lundbeck reports second quarter revenue of DKK 3,432 million growing 18% in constant exchange rates compared to its second quarter in 2008. Revenue in the US rising to DKK 1,025 million, with Lundbeck for the first time contributing a full quarter.
Key products Cipralex®, Ebixa® and Azilect® all experienced double digit growth in constant exchange rates and continues to gain market shares.
Lundbeck reports second quarter revenue of DKK 400 million, with Xenazine® sales already contributing DKK 81 million.
The performance of Xenazine® combined with the acquisition of LifeHealth Limited strengthens the US platform and supports further earnings from the second half of 2009 and onwards.
Profit from operations (EBIT) was DKK 719 million, including adjustments for acquisition accounting lowering EBIT with DKK 98 million. The EBIT margin for the period was 21%. Operating profit before depreciation and amortisation (EBITDA) was DKK 872 million corresponding to an EBITDA margin of 25%.
The tax rate for the full year is now expected to be 25-26%, as opposed to previously guided 28%.
Lundbeck maintains the financial guidance for the full year.